Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~General Inclusion Criteria:~* At least one bi-dimensionally measurable lymphoma lesion on CT scan defined as \> 1.5 cm in its longest dimension, which is also FDG avid by screening PET scan.~* Confirmed availability of archival or freshly biopsied tumor tissue prior to study enrollment~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~* Adequate hematologic function~* For female participants of childbearing potential, agreement to use highly effective forms of contraception~Dose-Escalation Portion of the Study:~* Participants must have histologically confirmed B-cell NHL, except MCL or SLL~* Participants must have never received previous R-CHOP treatment~* Any relapsed/refractory participants that are enrolled during the dose escalation should have received only a single previous treatment regimen~Expansion Portion of the Study:~* Participants must have previously untreated CD20-positive DLBCL and IPI score must be 2-5~Exclusion Criteria:~General Exclusion Criteria:~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products~* Contraindication to receive any of the individual components of CHOP, rituximab or obinutuzumab~* Prior anthracycline therapy~* Participants with ongoing corticosteroid use \>30 mg per day of prednisone or equivalent~* CNS lymphoma or primary mediastinal DLBCL~* Vaccination with live vaccines within 28 days prior to randomization~* Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1~* History of other malignancy that could affect compliance with the protocol or interpretation of results~* Evidence of significant, uncontrolled concomitant disease~* Significant cardiovascular disease or significant pulmonary disease~* Left ventricular ejection fraction less than (\<) 50% as defined by multiple-gated acquisition (MUGA)~* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1~* Received the following agents within 7 days prior to the first dose of venetoclax: steroid therapy for anti-neoplastic intent; strong and moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers; grapefruit/grapefruit products, seville oranges or star fruit within 3 days prior to the first dose of venetoclax~* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis~* Recent major surgery~* Women who are pregnant or lactating~Dose-Escalation Portion of the Study:~* Participants with confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma (SLL)~Expansion Portion of the Study:~* Participants with transformed lymphoma (participants with discordant bone marrow involvement (i.e., low grade histology in bone marrow) may be considered after discussion with the Medical Monitor)~* Prior therapy for NHL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Venetoclax + G-CHOP Arm (Type: EXPERIMENTAL): Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
- Venetoclax + R-CHOP Arm (Type: EXPERIMENTAL): Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).